Senolytics vs. NAD+ Boosters for Older Dogs: My Call on Which to Try First

By John Langlois, DVM, MSTCVM, CVA, CVMMP

Comparisons · August 22, 2026 · 5 min read

My verdict, up front: a combined senolytic-plus-NAD+ approach has trial data behind it; a standalone NAD+ precursor alone mostly does not, yet.

A twelve-year-old Cavalier King Charles Spaniel named Otis came into my practice last spring because his owner said he’d “gotten old overnight.” He’d stopped greeting them at the door, slept through the doorbell, and needed encouragement to take the stairs he used to bound up. His owner had already read about NAD+ chews online and wanted to know if that alone would bring him back. I told her what I’ll tell you here: it depends on what, specifically, is declining, and the two categories on the market right now — senolytics and NAD+ boosters — are not interchangeable tools even though the marketing often treats them that way.

The myth: NAD+ boosters and senolytics are basically the same pitch

Scroll through enough product pages and the two categories blur into one undifferentiated “cellular aging” pitch. They’re not the same mechanism. NAD+ precursors — nicotinamide riboside, nicotinamide mononucleotide — are substrates: they feed a cofactor dogs’ cells burn through faster as they age, supporting mitochondrial energy metabolism and sirtuin activity. Senolytics work differently. They’re compounds meant to help clear senescent cells, the “zombie” cells that stop dividing but linger and secrete inflammatory signals that appear to accelerate tissue decline. One replenishes fuel; the other tries to clean house. A dog can plausibly need either, both, or — at Otis’s stage — mostly something else entirely, like a mobility and pain workup.

What the actual trial data says

The strongest data point in this space right now is a randomized, controlled trial published in Scientific Reports testing a combined senolytic-and-NAD+-precursor compound, LY-D6/2, in seventy dogs with mild to moderate cognitive impairment. Dogs were split into placebo, low-dose, and full-dose groups, and owner-assessed cognitive dysfunction rating scale scores improved more in the full-dose group than in placebo from baseline to the trial’s endpoint. That’s a real signal, and it’s specific to the combination, not to NAD+ precursors given alone.

Standalone NAD+ precursor research in dogs is thinner. Most of what’s cited for nicotinamide riboside and nicotinamide mononucleotide traces back to rodent and human aging literature, plus the general physiological premise that NAD+ declines with age and that repletion supports cellular energy metabolism — reasonable extrapolation, but it is extrapolation, not a canine outcomes trial standing on its own. Separately, a large industry-backed study, Loyal’s LOY-002 program, is running as a four-year, roughly 1,000-dog trial through independent veterinary clinics, covered by dvm360, but that drug targets metabolic health pathways tied to insulin sensitivity and inflammation rather than being sold as an over-the-counter NAD+ supplement, and its results aren’t fully reported yet. Owners searching “NAD+ for dogs” often land on that momentum without realizing the flagship trial data belongs to a different, prescription-track product.

In my clinic, I’ve watched this play out with dogs in their eleventh and twelfth years whose owners had already tried an off-the-shelf NAD+ chew for two or three months with no noticeable change before they came to see me. One was a fourteen-year-old dachshund mix, thirteen pounds, whose owner had started an NAD+ supplement hoping it would help her get back on the couch unassisted. What actually turned out to matter was hip and lumbar discomfort limiting her push-off, something acupuncture and a joint-support plan addressed more directly than a cellular-energy supplement ever could. I’m not dismissing NAD+ precursors — the biology behind them is sound — but I’ve learned to ask what specifically is declining before reaching for either category, and that single question resolves the “senolytic vs. NAD+” debate faster than any product comparison chart does.

Where the evidence gets thin

Neither category has data on healthy-lifespan extension in dogs — no controlled trial has shown either senolytics or NAD+ precursors add years, and any product implying that is overstating what structure/function research supports. The strongest published trial (LY-D6/2) measured owner-assessed cognition over months, in dogs already showing cognitive impairment, not general wellness in an otherwise healthy senior. That’s a meaningfully narrower claim than “reverses aging,” and it’s worth reading the fine print on any product citing that Nature-family paper as backing for a broader promise. Dosing standardization is also inconsistent across the market — a real gap the Amazon Marketplace vs. Brand-Direct Websites for Dog Supplements comparison covers if you’re vetting sellers, since third-party listings can obscure batch and dosing information the manufacturer’s own site would show.

For any product in either category, checking for the NASC Quality Seal is a reasonable first filter — it doesn’t verify efficacy, but it does verify the manufacturer passed a facility audit and maintains ingredient traceability, which matters more in a category this new and this loosely regulated.

The sequence I actually recommend

First, separate the question. Is the decline mainly cognitive — disorientation, disrupted sleep-wake cycles, reduced interaction — or mainly physical, like stiffness, reduced jumping, or a change in gait after rest? The Arthritis vs. Normal Aging Stiffness in Dogs distinction matters here, because a joint-driven decline calls for a mobility-focused plan, sometimes including manual therapy, before a cellular-aging supplement is even on the table.

Second, if cognition is the primary concern and your dog already shows signs consistent with cognitive dysfunction, ask your vet about the specific senolytic-plus-NAD+-precursor combination that has trial data behind it rather than a generic NAD+ product chosen on brand strength alone. Third, if you’re leaning toward a standalone NAD+ precursor for general aging support, treat it as a structure/function add-on with a sound biological rationale, not a proven cognitive intervention, and give it a defined trial window — I typically suggest eight to twelve weeks — with the owner tracking specific markers rather than a vague sense of “seeming better.” Watch stairs, willingness to jump onto furniture, and gait quality after rest, the same concrete markers that told Otis’s owner and me something real was changing once we corrected the actual problem.

In practice, I lean on whole-patient balance rather than a single supplement swap — the Western literature on NAD+ and senescence sits alongside centuries of Chinese herbal and manual-medicine tradition treating aging as a whole-body pattern, not an isolated molecule to top off. Tui-na and acupuncture won’t replace a cellular pathway, but they change what I look for before I recommend one.

Where this leaves the verdict

Choosing between senolytics and NAD+ boosters isn’t really a brand decision — it’s a diagnostic one. If you can’t say why your dog is declining, no supplement category will fix that ambiguity for you.

For format questions once you’ve picked a category, Chew vs Powder vs Liquid Supplements for Dogs and Freeze-Dried vs Powder Supplements for Dogs cover how delivery format affects what actually reaches your dog.

Bottom line: the combined senolytic-and-NAD+-precursor approach has an actual randomized trial behind it for cognitive decline; a standalone NAD+ precursor rests on sound biology but thinner canine-specific proof, so match the category to a real diagnosis, not a marketing claim.